Fig. 4.
a. Schematic illustration of preparation of PAH/FA/PEG/GO siRNA complex. b. Fluorescent images of MIA PaCa-2 cells after receiving different treatments. (1) PBS (blank); (2) free K-Ras siRNACy3 + HDAC1 siRNAFAM (siRNACy3+FAM) and (3) FA/PEG/PAH/GO (FA/GO) (negative controls); (6) Oligofectamine-conjugated siRNA (Oligo/siRNACy3+FAM) and (7) Lipofectamine 2000 (Lipo/siRNACy3+FAM) (positive controls); and Kras-siRNACy3 and HDAC1-siRNAFAM co-delivery by GO/PEG/PAH (GO/siRNACy3+FAM) or GO/PEG/PAH/FA (GO/FA/siRNACy3+FAM). The cell nuclei were stained with DAPI (pseudo-colored in blue), and signals from FAM and Cy3 were designated in green and red, respectively. Bright field images were merged with DAPI and siRNACy3+FAM (overlaid) to indicate the cell-penetrating abilities of different complexes. c. Relative protein levels in MIA PaCa-2 cells with different GO-based nano-formulations treatments. The results were measured with western blotting, and actin was used as the protein loading control. Data were presented as means ± s.e.m. of triplicate experiments. **P < 0.01 vs PBS (blank). Tumor images (d) and weight (e) of tumor-bearing mice treated with (1) PBS, (2) FA/GO/scramble siRNA, (3) FA/GO with NIR light, (4) FA/GO/(H+K) siRNA or (5) FA/GO/(H+K) siRNA with NIR light. Cited and reproduced from the reference [92].